MIKE WORFUL
Robert Bucelli, MD, PhD, measures Gregory Easter’s neuromuscular function. Easter, who has an inherited form of amytrophic lateral sclerosis, a fatal neuromuscular disease, is taking part in a clinical trial to evaluate an experimental drug. New research at Washington University School of Medicine in St. Louis shows the drug extends survival and reverses some neuromuscular damage in mice and rats and may help people whose disease is caused by mutations in the gene SOD1.
Drug extends survival, reverses some neuromuscular damage in animals
About 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The invariably fatal disease kills the nerve cells that control walking, eating and breathing. Few people survive more than three years after diagnosis.
Now, new research led by Washington University School of Medicine in St. Louis indicates an investigational therapy for an inherited form of ALS extends survival and reverses signs of neuromuscular damage in mice and rats. The findings, published July 16 in The Journal of Clinical Investigation, have led to a phase one/two clinical trial to investigate whether the drug could benefit people with ALS whose disease is caused by mutations in a gene called SOD1.
“This drug had an impressive effect in mice and rats with just one or two doses,” said Timothy Miller, MD, PhD, the David Clayson Professor of Neurology at Washington University. “We don’t know yet if this works in people, but we’re very hopeful. We’ve completed the first phase of safety testing, and now we’re working on finding the right dose.”
About 10 percent of ALS cases are inherited. Of those, about a fifth are caused by mutations in SOD1. Such mutations cause the SOD1 protein to be overly active, which suggests that reducing protein levels might help ALS patients with SOD1 mutations.
Patients with ALS have few options for treatment. Only two drugs have been approved by the Food and Drug Administration (FDA) for ALS, and both only modestly slow the course of the disease.
In collaboration with Ionis Pharmaceuticals, Miller and colleagues tested DNA-based compounds that block the body from making SOD1 protein.
Miller and colleagues at Ionis tested two such compounds – known as antisense oligonucleotides, or oligos for short – in mice and rats. The animals were genetically modified to carry a mutated form of the human SOD1 gene. By a few months old, such animals start having trouble walking and feeding themselves.
Mice were given an anti-SOD1 oligo or a placebo at day 50, and a second dose about six weeks later. The mice that received the active drug maintained their weight 26 days longer and lived 37 days longer than those given the placebo, an increase in life span of 22 percent.
As a comparison, the researchers also tested the treatment in rats. The rats that received an active oligo fared much better than the ones that received the placebo. They maintained their weight more than nine weeks longer and survived eight to nine weeks longer.
The oligos also reversed signs of neuromuscular damage in the animals. By nine weeks old, mice that carry the mutant SOD1 gene are already showing molecular signs of deteriorating neuromuscular function. To find out whether the drug could reverse this decline, researchers treated 9-week-old mice with an anti-SOD1 oligo or a placebo. Muscle function steadily improved over the next eight weeks in the mice that received the active drug, while it continued to decline in the placebo group. A sign of neurological damage rose in both groups, but it rose more than twice as quickly in the mice that received the placebo than the ones given the active oligo.
Miller’s colleague at the School of Medicine, Robert Bucelli, MD, PhD, an associate professor of neurology, leads a phase one/two clinical trial based on Miller’s research. The trial is designed to evaluate the safety of using the oligos in people. Initial safety testing did not identify any obvious hazards. Now, they are testing different doses and regimens to find the most effective way to reduce SOD1 levels without causing unacceptable side effects.
“The phase one/two trial is really still a safety trial,” Miller said. “There are not enough patients in it to really be able to accurately see an effect on disease. But we’re on the cusp of testing the hypothesis that people with ALS caused by mutations in SOD1 can benefit from this treatment. We predict the effect will be good, but we can’t know until we test it.”
Learn more: New ALS therapy in clinical trials
The Latest on: ALS therapy
via Google News
The Latest on: ALS therapy
- A new ALS drug is extending patients' lives by months. It's giving hope for those facing such a 'brutal illness.'on March 3, 2021 at 8:19 am
With ALS treatments, success is measured by extending patients' lives by months. Some hope new drugs now being tested could slow the disease.
- FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefiton March 3, 2021 at 7:54 am
A Brainstorm Cell Therapeutics therapy for Lou Gehrig’s disease failed a pivotal study, but the company points to better results in a subgroup. The FDA took the unusual step of publicly stating that ...
- 'No time to wait': ALS drug trials create hope among researchers, patientson March 3, 2021 at 3:06 am
With ALS treatments, success is measured by extending patients' lives by months. Some hope new drugs now being tested could slow the disease.
- ALS nonprofit moving lab, HQ to Watertownon March 2, 2021 at 7:56 am
The ALS Therapy Development Institute, a drug discovery lab focused solely on finding treatments for ALS, is moving its headquarters from Cambridge to Watertown to support the continued growth of its ...
- NeuroSense Therapeutics Reports Positive Results in Phase IIa Clinical Study in ALS and Patent Allowance in the USA for PrimeCon March 2, 2021 at 7:34 am
NeuroSense Therapeutics, a biotechnology company developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), based on a novel combination drug therapy aiming at ...
- Orphazyme reports business highlights and financial results in Annual Report 2020on March 1, 2021 at 11:24 pm
Orphazyme A/S Company announcement No. 06/2021 Company Registration No. 32266355-Advanced arimoclomol in 4 rare disease indications; announced global brand name of arimoclomol (MI ...
- Update on Amyotrophic Lateral Sclerosis (ALS) Product Developmenton March 1, 2021 at 6:48 pm
FDA knows that ALS patients, their families, and others in the ALS community have been closely watching the development of BrainStorm Cell Therapeutics, Inc.’s NurOwn therapy. From data that have been ...
- Orphazyme appoints Christophe Bourdon as Chief Executive Officeron February 28, 2021 at 10:59 pm
Orphazyme A/S (ORPHA.CO; ORPH) ("Orphazyme"), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced ...
- Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlightson February 26, 2021 at 3:16 am
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases ...
via Bing News